Dr Reddy's to manufacture baricitinib for Covid treatment
By
IANS
|
Published on
Wed, May 12 2021 11:03 IST
|
3 Views
Mumbai Port Trust to sign MoUs of worth Rs 1,860 cr at Maritime Summit. Image Source: IANS News
Hyderabad, May 12 : Pharma major Dr. Reddy's Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of baricitinib in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).